Skip to content

Gene Expression in Monocytes of Growth Hormone Deficient Children

Growth Hormone Modulated Gene Expression in Monocytes of Healthy and Growth Hormone Deficient Children

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04352712
Acronym
GEMGH
Enrollment
40
Registered
2020-04-20
Start date
2019-04-15
Completion date
2021-04-15
Last updated
2020-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Hormone Deficiency

Brief summary

The Growth hormone (GH) is mainly synthesized in the anterior portion of the pituitary gland and has an effect on different body areas. Secreted in the circulatory stream, growth hormone reaches the liver and here stimulates the secretion of somatomedin C better known as insulin-like growth factor 1 (IGF), which constitutes its main anabolic effector. Growth hormone deficiency (GHD) is characterized by a delay in the statural growth in children and is correlated with a worsening of body composition, cognitive functions, lipid metabolism, bone mineralization, cardiac performance and exercise in adults. Recombinant GH (rhGH) replacement therapy can correct these alterations and therefore improve the quality of life in treated patients, and accelerate growth in children. The optimal dosage of rhGH varies for each patient, as the response to treatment suffers from considerable inter-individual variability. To date, IGF1 is the only available biomarker whose plasma levels correlate with replacement therapy. It is important to underline how somatomedin C does not provide information about the optimal posology of rhGH for each patient in order, therefore, to predict its adverse events and efficacy. In addition, it has been shown that the effects mediated by the somatotropic hormone on some tissues are direct, therefore independent of the action of IGF1, whose plasma levels are not, in this case, predictive of therapeutic response. For this reason, it is therefore necessary to identify a more specific biomarker capable of monitoring the efficacy, individual responsiveness and any adverse events in patients receiving somatotropic hormone. The GH receptor (GHR) is expressed in several cells, including monocytes. It is therefore possible that the response of monocytes to the somatotropic hormone partially mirrors that of the chondrocyte and other cell types. Given the difficulty of obtaining osteomuscular biopsies or specific body areas in which GH mediates its biological action, the published works have identified the specific cell line in which to study the molecular effects of the hormone in monocytes, thanks to their easy accessibility and high number of GHR. In consideration of this, the investigators propose to stimulate monocytes of healthy and GHD children in vitro with rhGH and through next generation sequencing to identify the characteristic gene expression profile. The GH responsive genes identified with this study can be used for correlation studies on the response to rhGH treatment.

Interventions

OTHERblood sampling

blood sampling

Sponsors

University of Salerno
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
6 Years to 10 Years
Healthy volunteers
Yes

Inclusion criteria

* Height lower the 3th percentile

Exclusion criteria

* Any endocrinopathy * Liver, kidney or haemolymphopoietic system disorders * Celiac disease or other chronic malabsorption conditions * Genetic syndromes (such as Turner's S., Cystic fibrosis or Down S.) * Drug therapies interfering with growth

Design outcomes

Primary

MeasureTime frameDescription
gene expression in monocytes of GHD childrenone yearanalysis of RNA-seq of monocytes of healthy and GHD children

Secondary

MeasureTime frameDescription
gene expression in monocytes modulated by GHone yearanalysis of RNA-seq of monocytes of healthy and GHD children, stimulated with GH in culture

Countries

Italy

Contacts

Primary ContactMario Vitale, MD
mavitale@unisa.it393482652847

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026